Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LEXX vs SRZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–0 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: LEXX 2 – 3 SRZN (1 Tie) Matrix Metrics: LEXX 0 – 7 SRZN

As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Lexaria Bioscience Corp. (LEXX) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LEXX carries a Unified Composite Score of 33.3/100 (SELL) at $4.41 (N/M Forward P/E, -3862.9% operating margin), whereas SRZN carries 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin).

  • Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both LEXX (33.3/100 SELL) and SRZN (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LEXX vs SRZN
LEXX NASDAQ
Lexaria Bioscience Corp. Common Stock
Pharmaceutical Preparations
$4.41
-0.68% 1D
Market Cap $9.4M
TTM Revenue $194,000
Forward P/E N/M
Beta / 30D Vol 11.09β · 92% Vol
Unified Composite Score
33.3 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.0 · SMA20: $3.78 · SMA50: $3.62
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.21β · 62% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 5.0 Fund 32.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.1% over 20 days), RSI 61
RSI-14: 61.3 · SMA20: $29.51 · SMA50: $26.10

6-Pillar Scorecard Institutional Category Breakdown (LEXX 2 – 3 SRZN)

Columns: Metric · LEXX · SRZN
1. Valuation Multiples LEXX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 30.7x 48.3x
2. Growth & Scale SRZN
Revenue Growth (YoY) -88.5% +408.6%
Earnings Growth (YoY) +0.0% -37.0%
TTM Revenue (USD) $194,000 $11M
Market Cap $9.4M $602.5M
3. Profitability & Quality SRZN
Gross Margin 100.0% N/A
Operating Margin -3862.9% -485.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -162.8% -62.8%
4. Balance Sheet & Cash Flow LEXX
Cash Generation (TTM) -$7.5M -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.4M Net Cash $95M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 72.0% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LEXX (0) vs SRZN (7)
Institutional Metric LEXX SRZN Criterion Row Edge
Market Capitalization
Scale
$9.4M $602.5M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-88.5% +408.6% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-3862.9% -485.4% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-162.8% -62.8% Higher ROE SRZN
52-Week Range Position
Momentum
29% ($0–$14) 79% ($12–$38) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
11.09β · 92% Vol 1.21β · 62% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
33.3 / 100 (SELL) 34.3 / 100 (SELL) Higher Composite SRZN
Trailing 12M Revenue (USD)
Operating Scale
$194,000 $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 30.7x EV/Rev N/M PEG · 48.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.5M ($3.4M Net Cash) -$31M ($95M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LEXX +16.32 pp
LEXX: +54.2% · SRZN: +37.88%
3M Horizon SRZN +96.39 pp
LEXX: -61.72% · SRZN: +34.67%
6M Horizon LEXX +669.58 pp
LEXX: +687.36% · SRZN: +17.78%
1Y Horizon LEXX +134.24 pp
LEXX: +300.91% · SRZN: +166.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LEXX Revenue SRZN Revenue LEXX Op. Margin SRZN Op. Margin Margin Leader
FY2018 $0M N/A -1525.4% N/A LEXX
FY2019 $0M N/A -1868.0% N/A LEXX
FY2020 $0M N/A -1062.2% N/A LEXX
FY2021 $0M N/A -786.8% N/A LEXX
FY2022 $0M $10M -2591.7% -354.7% SRZN
FY2023 $0M N/A -2888.5% N/A LEXX
FY2024 $0M $10M -1239.2% -239.7% SRZN
FY2025 $0M $0M -1683.0% -1210.6% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LEXX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LEXX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
37d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LEXX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.4M market capitalization and -3862.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LEXX vs SRZN Key Questions & Quantitative Answers

As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Lexaria Bioscience Corp. (LEXX) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LEXX carries a Unified Composite Score of 33.3/100 (SELL) at $4.41 (N/M Forward P/E, -3862.9% operating margin), whereas SRZN carries 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin). Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both LEXX (33.3/100 SELL) and SRZN (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SRZN leads the Growth & Scale pillar: LEXX posts -88.5% YoY revenue growth and +0.0% YoY earnings growth on $194,000 TTM revenue (100.0% gross margin, -3862.9% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LEXX cumulative revenue shifted N/A while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, LEXX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.

LEXX screens cheaper on headline valuation multiples. LEXX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 30.7x EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LEXX (-162.8% ROE) versus SRZN (-62.8% ROE) capital efficiency.

In options market volatility and institutional positioning, LEXX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (11.09β · 92% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.